Eli Lilly is poised to capitalize on explosive growth in India for its diabetes and weight-loss drug Mounjaro, with sales doubling in July to 157,000 units—equivalent to 470 million rupees. Since its March launch, demand has surged 15-fold, solidifying its lead over rival Novo Nordisk’s Wegovy, which saw slower traction despite a recent sales doubling. Analysts highlight Eli Lilly’s established prescriber base as a key advantage, while Novo Nordisk faces steep marketing costs to compete. The strong Indian performance could bolster Eli Lilly’s upcoming quarterly earnings, offering optimism after Novo Nordisk’s recent profit warning and stock plunge.
Healthcare Sector Shifts Favor Eli Lilly
The company now leads the Polar Capital Global Healthcare Trust’s portfolio at 7.2%, reflecting institutional confidence as Novo Nordisk struggles. Despite Wegovy’s 67% revenue jump, Novo Nordisk posted its weakest growth in four years, with shares losing over $400 billion since June. Eli Lilly’s dominance underscores a broader market shift toward U.S. pharma giants, with 47.2% of the trust’s holdings in American firms. As competition intensifies, Eli Lilly’s strategic positioning and robust demand in emerging markets signal sustained momentum.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from November 9 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 9.
Eli Lilly: Buy or sell? Read more here...
